Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Opioids Pending At FDA Held Up By Anti-Abuse Claims, Not REMS Planning

Executive Summary

Opioid products awaiting FDA approval are not being put on hold for completion of a Risk Evaluation and Mitigation Strategy, said Office of New Drugs Director John Jenkins

You may also be interested in...

Embeda Uptake In Primary Care Depends On FDA Clearing Marketing Materials, King Says

After a warning letter, Embeda sales effort focuses on specialists. Firm does not see franchise threat from generics, although Remoxy will not be refiled until the middle of next year.

Second Time Around: Joint Advisory Committee Will Review Purdue's OxyContin Again

Purdue's OxyContin will get another advisory committee review Sept. 24, 2009, in light of new data.

Chew On This: FDA OK's King's Tamper-Resistant Morphine, Embeda

Embeda to launch in September backed by 610 sales reps, Chief Commercial Officer Andrzejewski says.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts